DISCOVER SYLENTIS
Media

If you need to contact our communication department, please do it by contacting:

  • Miguel Martínez-Cava
  • Olaya Fernández Díez
  • Pharma Mar Communication Dept.
  • Phone: +34 91 846 6000

Press releases

Sylentis, a PharmaMar Group company, begins a new Phase II trial with SYL1801 for patients with Age-Related Macular Degeneration

Madrid, November 23rd, 2022. – Sylentis, a PharmaMar Group Company (MSE:PHM), has announced today the recruitment of the first patient
23 de November de 2022

Sylentis, a wholly owned subsidiary of PharmaMar, inaugurates first oligonucleotide manufacturing plant in Spain

The plant, which has a surface area of 400m2, will serve both Sylentis’ manufacturing needs and those of other pharmaceutical
19 de April de 2022

Sylentis initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease

This Phase III study, called FYDES, will involve 26 hospitals in the United States. It will evaluate the long-term safety
1 de April de 2022

Sylentis, PharmaMar Group, completes Phase I trial with SYL1801 for retinal diseases

This trial involved 36 healthy volunteers who were administered eye drops for the treatment and/or prevention of retinal diseases, such
14 de March de 2022

Sylentis, PharmaMar Group, initiates a Phase I clinical trial with SYL1801 for retinal diseases

This Phase I trial will enroll 36 healthy volunteers and will be conducted at the Hospital Universitario Ramón y Cajal
18 de March de 2021

Sylentis, a pioneer in RNAi technology, obtains authorisation as research drug manufacturing laboratory

Sylentis, a biopharmaceutical company in Grupo Zeltia (MC:ZEL) which is a pioneer in the research and development of new drugs based on gene silencing (interference RNA: RNAi) and one of the four companies in the world with RNAi-based products undergoing clinical trials, has been authorised as a pharmaceutical laboratory to

Sylentis presents new results on its ophthalmological compounds at ARVO 2018

The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies. The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be

Sylentis presents new data on a new eye drop siRNA for the treatment of retinal diseases avoiding intraocular injections

This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients’ quality of life by eluding the use of current standard treatments administered by intraocular injections.   Madrid, 25 September 2017. Sylentis presents, for the first time,

Sylentis presented new results for the treatment of age associated macular degeneration

Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization .   Madrid, 4th of May, 2018. Within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), that has

Zeltia subsidiary Sylentis commences Phase I trials with its new compound SYL1001 to treat eye pain associated with dry eye syndrome

SYL1001 is a new compound arising from Sylentis’s research in ophthalmological disorders  It is indicated for treating eye discomfort associated with dry eye syndrome  SYL1001 is a form of interference RNA (RNAi)  SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye

Sylentis receives authorisation to commence Phase IIb clinical trial with bamosiran (SYL040012) for treating ocular hypertension associated with glaucoma

The main endpoint of the trial is to establish the most effective dose of bamosiran for reducing intraocular pressure after 28 days’ treatment.  The Phase IIb trial with bamosiran will be conducted at 21 centres in Spain, Germany, Estonia and the United States, enrolling 180 patients. Madrid, 17 July 2014: Grupo

Sylentis sponsors the 11th OTS’s Annual Meeting

Sylentis sponsors the 11th Annual meeting of the Oligonucleotide Therapeutics Society (OTS). The meeting will be held in Leiden (The Netherlands) 11-14th October, 2015. Oligonucleotide Therapeutics Society is an open, nonprofit forum to foster academia and industry-based research and development of oligonucleotide therapeutics. You can find more information about this event

Sylentis – Treatment commences for first patients in Phase I/II clinical trial with SYL040012

SYL040012 is a new compound developed in Sylentis’s R&D programme in ophthalmological disorders such as ocular hypertension and glaucoma. SYL040012 is a form of RNA interference (RNAi). It reduces intraocular pressure by inhibiting the expression of ß-adrenergic receptors. Madrid, 22 November 2010: Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL)

Sylentis participates in the 7th Spanish Conference on Glaucoma (SEG)

Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an oral communication entitled “Phase I Trial with SYL040012: New RNAi-based treatment for glaucoma”

Sylentis announces new preclinical and clinical data for its SYL1001 molecule during ARVO 2017

SYL1001 is a compound under investigation for the treatment of dry eye disease. It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness. At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017,
error: Content is protected !!